Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Psychiatry/Psychology | Neurology | Family Medicine
Clinical Trials: Depression (Major/Severe)
A listing of clinical trials currently looking for volunteers to enroll in Depression (Major/Severe) studies. Click on the closest city to find more detailed information on a research study in your area.
California
Connecticut
Hartford : Hartford Hospital - Institute of Living
The purpose of this research study is to evaluate the efficacy (how well the drug works), safety (the side effects), and tolerability (how well tolerated) of vilazodone compared to placebo (an inactive substance or sugar pill) in patients with depression.
Waterbury : Chase Medical Research, LLC
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.
Florida
Georgia
Illinois
Hoffman Estates : Alexian Brothers Hospital Network
A multicenter, randomized, double-blind study to evaluate the efficacy, safety and tolerability of an oral Aripiprazole-Escitalopram combination therapy in patients with Major Depressive Disorder.
Hoffman Estates : Alexian Brothers Hospital Network
A multicenter, randomized, double-blind, parallel group, placebo controlled, phase III, efficacy and safety study of 3 fixed dose groups of TC-5214 (S-mecamylamine) as an adjunct to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate resopnse to antidepressant therapy.
Hoffman Estates : Alexian Brothers Hospital Network
A phase 3, randomized, double blind, parallel group, placebo-controlled, fixed dose study comparing the efficacy and safety of 2 doses (10 and 15mg) of Lu AA21004 in acute treatment of adults with major depressive disorder.
Hoffman Estates : Alexian Brothers Hospital Network
A randomized, placebo-controlled, double-blind study of Ly2216684 flexible dose 12 mg to 18 mg once daily and LY2216684 fixed dose 6 mg once daily as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
Hoffman Estates : Alexian Brothers Hospital Network
An 8-week, randomzied, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of agomelatine 0.5mg and 1mg sublingual tablets administered once daily in patients with Major Depressive Disorder (MDD).
Skokie : Psychiatric Medicine Associates/John Zajecka, M.D.
Depression Research Study
Skokie : Psychiatric Medicine Associates/John Zajecka, M.D.
Depression Research Study for adults who are currently taking an antidepressant but still experiencing some symptoms of depression
Kentucky
Edgewood : OtriMed Clinical Research
Adult Major Depressive Disorder Clinical Trial
Louisiana
Lake Charles : Lake Charles Clinical Trials
Efficacy and safety study of adjunctive AZD6765 in subjects with severe Major Depressive Disorder and a history of poor response to antidepressants
Massachusetts
Haverhill : ActivMed Practices & Research, Inc.
Are you between the ages of 18 and 65 and suffering from Depression?
Haverhill : ActivMed Practices & Research, Inc.
Feeling better, but not where you want to be?
New Jersey
New York
New York : Clinilabs, Inc.
Are your Major Depressive Disorder medications not working?
New York : Clinilabs, Inc.
Have you been diagnosed with major depression? Do you continue to have symptoms despite medications?
New York : Clinilabs, Inc.
Have you been diagnosed with major depression? Do you continue to have symptoms despite medications?
Ohio
Cincinnati : Community Research
Major Depressive Disorder (MDD)
Pennsylvania
Tennessee
Texas
Utah
Salt Lake City : CRI Lifetree
To assess the Safety and Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression
Salt Lake City : CRI Lifetree
To demonstrate the efficacy and safety of CORLUX (mifepristone) followed
by an antidepressant compared to placebo followed by an antidepressant in the treatment of psychosis in patients with Major Depressive Disorder with psychotic features (DSM-IV 296.24 or 296.34).